Genes associados às cardiopatias congênitas no cenário de diabetes materno
Reference14 articles.
1. ASOGLU, M. R. et al. Exposure of the developing heart to diabetic environment and early cardiac assessment: A review. Echocardiography, v. 35, n. 2, p. 244–257, 21 jan. 2018. 2. BASU, M.; GARG, V. Maternal hyperglycemia and fetal cardiac development: Clinical impact and underlying mechanisms. Birth Defects Research, v. 110, n. 20, p. 1504–1516, 1 dez. 2018. BRUNEAU, B. G. The developmental genetics of congenital heart disease. Nature, v. 451, n. 7181, p. 943–948, fev. 2008. 3. CHOUDHURY, T. Z. et al. Impact of maternal hyperglycemia on cardiac development: Insights from animal models. genesis, v. 59, n. 11, 9 set. 2021. ENGINEER, A. et al. Sapropterin Treatment Prevents Congenital Heart Defects Induced by Pregestational Diabetes Mellitus in Mice. Journal of the American Heart Association, v. 7, n. 21, 6 nov. 2018. 4. ENGINEER, A. et al. Say NO to ROS: Their Roles in Embryonic Heart Development and Pathogenesis of Congenital Heart Defects in Maternal Diabetes. Antioxidants, v. 8, n. 10, 1 out. 2019. 5. JARRELL; LENNON; JACOT. Epigenetics and Mechanobiology in Heart Development and Congenital Heart Disease. Diseases, v. 7, n. 3, p. 52, 1 set. 2019.
|
|